

Gianfranco Ferraccioli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5690495/publications.pdf>

Version: 2024-02-01

301
papers

23,647
citations

15504

65
h-index

8396

147
g-index

305
all docs

305
docs citations

305
times ranked

20688
citing authors

#	ARTICLE	IF	CITATIONS
1	2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2010, 62, 2569-2581.	6.7	6,781
2	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1580-1588.	0.9	2,994
3	EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 34-45.	0.9	651
4	Efficacy and safety of rituximab in type II mixed cryoglobulinemia. <i>Blood</i> , 2003, 101, 3827-3834.	1.4	471
5	Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 909-920.	0.9	394
6	2016 update of the EULAR recommendations for the management of early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 948-959.	0.9	393
7	Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. <i>Arthritis Research and Therapy</i> , 2008, 10, R30.	3.5	387
8	Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis. <i>Arthritis and Rheumatism</i> , 2007, 56, 3896-3908.	6.7	310
9	Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis. <i>Nature Medicine</i> , 2020, 26, 1295-1306.	30.7	304
10	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. <i>Arthritis and Rheumatism</i> , 2010, 62, 2582-2591.	6.7	246
11	Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: Evidence for a pathogenetic role of B cells. <i>Arthritis and Rheumatism</i> , 2002, 46, 2029-2033.	6.7	240
12	EULAR definition of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 31-35.	0.9	224
13	Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA Study. <i>Arthritis Research and Therapy</i> , 2010, 12, R42.	3.5	217
14	Prednisone plus Methotrexate for Polymyalgia Rheumatica. <i>Annals of Internal Medicine</i> , 2004, 141, 493.	3.9	204
15	Consensus statement on the use of rituximab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 143-150.	0.9	194
16	Hepatitis C virus within a malignant lymphoma lesion in the course of type II mixed cryoglobulinemia. <i>Blood</i> , 1995, 86, 1887-1892.	1.4	174
17	Clinical and ultrasonographic remission determines different chances of relapse in early and long standing rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 172-175.	0.9	172
18	Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. <i>Rheumatology</i> , 2006, 45, 842-846.	1.9	170

#	ARTICLE	IF	CITATIONS
19	Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: An approach to a personalized medicine. <i>Arthritis Care and Research</i> , 2013, 65, 94-100.	3.4	170
20	MicroRNA-155 at the Critical Interface of Innate and Adaptive Immunity in Arthritis. <i>Frontiers in Immunology</i> , 2017, 8, 1932.	4.8	170
21	The role of biosimilars in the treatment of rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 322-328.	0.9	166
22	B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. <i>Arthritis Research and Therapy</i> , 2010, 12, R54.	3.5	162
23	Remission and rheumatoid arthritis: Data on patients receiving usual care in twenty-four countries. <i>Arthritis and Rheumatism</i> , 2008, 58, 2642-2651.	6.7	156
24	A Randomized Pilot Trial Comparing Cyclosporine and Azathioprine for Maintenance Therapy in Diffuse Lupus Nephritis over Four Years. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 925-932.	4.5	146
25	Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry. <i>Autoimmunity Reviews</i> , 2012, 12, 225-229.	5.8	146
26	Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: Clinical and molecular findings do not support a bone marrow pathologic diagnosis of indolent B cell lymphoma. <i>Arthritis and Rheumatism</i> , 2000, 43, 94-102.	6.7	142
27	Brief Report: Successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: An Italian multicenter study. <i>Arthritis and Rheumatism</i> , 2012, 64, 1970-1977.	6.7	134
28	Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 428-436.	3.4	130
29	Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. <i>Rheumatology</i> , 2015, 54, 891-898.	1.9	129
30	Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. <i>British Journal of Rheumatology</i> , 2002, 41, 1346-1356.	2.3	124
31	Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study. <i>Arthritis and Rheumatology</i> , 2016, 68, 2527-2539.	5.6	122
32	Recognizing and treating myocarditis in recent-onset systemic sclerosis heart disease: Potential utility of immunosuppressive therapy in cardiac damage progression. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 526-535.	3.4	119
33	TNF- α , rheumatoid arthritis, and heart failure: a rheumatological dilemma. <i>Autoimmunity Reviews</i> , 2005, 4, 153-161.	5.8	118
34	Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 858-862.	0.9	112
35	Obesity as a Risk and Severity Factor in Rheumatic Diseases (Autoimmune Chronic Inflammatory) Tj ETQq1 1 0.784314 rgBT /Overloc	4.8	110
36	Salivary gland B cell lymphoproliferative disorders in Sjögren's syndrome present a restricted use of antigen receptor gene segments similar to those used by hepatitis C virus-associated non-Hodgkin's lymphomas. <i>European Journal of Immunology</i> , 2002, 32, 903.	2.9	104

#	ARTICLE	IF	CITATIONS
37	Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: A two-year, double-blind, randomized study. <i>Arthritis and Rheumatism</i> , 2010, 62, 674-682.	6.7	104
38	Body weight, gender and response to TNF- α blockers in axial spondyloarthritis. <i>Rheumatology</i> , 2014, 53, 875-881.	1.9	104
39	EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 20-33.	0.9	104
40	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 482-492.	0.9	102
41	Characterization of prelymphomatous stages of B cell lymphoproliferation in Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 1997, 40, 318-331.	6.7	100
42	Interleukin-1 β and Interleukin-6 in Arthritis Animal Models: Roles in the Early Phase of Transition from Acute to Chronic Inflammation and Relevance for Human Rheumatoid Arthritis. <i>Molecular Medicine</i> , 2010, 16, 552-557.	4.4	100
43	B-Lymphocyte stimulator (BLyS) up-regulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection. <i>Rheumatology</i> , 2007, 46, 37-43.	1.9	99
44	MicroRNA-155 influences B-cell function through PU.1 in rheumatoid arthritis. <i>Nature Communications</i> , 2016, 7, 12970.	12.8	97
45	Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008, 35, 1256-64.	2.0	95
46	The metabolic syndrome: The crossroads between rheumatoid arthritis and cardiovascular risk. <i>Autoimmunity Reviews</i> , 2011, 10, 582-589.	5.8	90
47	Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. <i>Arthritis and Rheumatism</i> , 2008, 59, 32-41.	6.7	89
48	Usefulness of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography in patients with large-vessel vasculitis: a systematic review. <i>Clinical Rheumatology</i> , 2011, 30, 1265-1275.	2.2	89
49	Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. <i>Rheumatology</i> , 2012, 51, 157-168.	1.9	89
50	Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , 2017, 8, 369.	3.5	89
51	The need for personalised medicine for rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 4-7.	0.9	88
52	Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 358-361.	0.9	86
53	Gastric mucosa as an additional extrahepatic localization of hepatitis C virus: Viral detection in gastric low-grade lymphoma associated with autoimmune disease and in chronic gastritis. <i>Hepatology</i> , 2000, 31, 182-189.	7.3	83
54	Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. <i>Clinical Rheumatology</i> , 2016, 35, 1683-1689.	2.2	83

#	ARTICLE	IF	CITATIONS
55	Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. <i>Journal of Rheumatology</i> , 2008, 35, 1944-9.	2.0	82
56	Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin a. <i>Arthritis and Rheumatism</i> , 1996, 39, 1006-1015.	6.7	80
57	TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2008, 27, 833-839.	2.2	80
58	Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 583-589.	0.9	80
59	IL-1B and IL-1RN gene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy. <i>Pharmacogenomics</i> , 2006, 7, 683-695.	1.3	75
60	Skin ulcers in systemic sclerosis: Determinants of presence and predictive factors of healing. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 426-435.	1.2	73
61	MicroRNA-34a dependent regulation of AXL controls the activation of dendritic cells in inflammatory arthritis. <i>Nature Communications</i> , 2017, 8, 15877.	12.8	72
62	Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-progression. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1292-1295.	0.9	71
63	Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1228-1236.	0.9	70
64	B cells in systemic sclerosis: A possible target for therapy. <i>Autoimmunity Reviews</i> , 2011, 10, 624-630.	5.8	68
65	Validation of the classification criteria for cryoglobulinaemic vasculitis. <i>Rheumatology</i> , 2014, 53, 2209-2213.	1.9	67
66	Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study. <i>Rheumatology</i> , 2015, 54, 792-797.	1.9	67
67	Clinical heterogeneity of SAPHO syndrome: challenging diagnose and treatment. <i>Clinical Rheumatology</i> , 2017, 36, 2151-2158.	2.2	67
68	The human salivary proteome: a critical overview of the results obtained by different proteomic platforms. <i>Expert Review of Proteomics</i> , 2012, 9, 33-46.	3.0	65
69	Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis. <i>Respiratory Research</i> , 2005, 6, 96.	3.6	64
70	Tapering and discontinuation of TNF-Î± blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission. <i>Arthritis Research and Therapy</i> , 2016, 18, 39.	3.5	62
71	Peripheral neuropathy in essential mixed cryoglobulinaemia.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1992, 55, 116-120.	1.9	60
72	Endothelial progenitors in pulmonary hypertension: new pathophysiology and therapeutic implications. <i>European Respiratory Journal</i> , 2010, 35, 418-425.	6.7	60

#	ARTICLE	IF	CITATIONS
73	Mild Sialoadenitis: A Common Finding in Patients with Hepatitis C Virus Infection. <i>Scandinavian Journal of Gastroenterology</i> , 1994, 29, 940-942.	1.5	58
74	Rituximab for the treatment of type II mixed cryoglobulinemia. <i>Arthritis and Rheumatism</i> , 2002, 46, 2252-2254.	6.7	56
75	Synovial fluid-derived T helper 17 cells correlate with inflammatory activity in arthritis, irrespectively of diagnosis. <i>Clinical Immunology</i> , 2011, 138, 107-116.	3.2	55
76	<i>Porphyromonas gingivalis</i> and the pathogenesis of rheumatoid arthritis: analysis of various compartments including the synovial tissue. <i>Arthritis Research and Therapy</i> , 2013, 15, R66.	3.5	55
77	Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 449-56.	0.8	55
78	Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2002, 29, 1847-50.	2.0	53
79	Intravascular tumor necrosis factor $\hat{\pm}$ blockade reverses endothelial dysfunction in rheumatoid arthritis. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 275-281.	4.7	52
80	Patient-reported impact of spondyloarthritis on work disability and working life: the ATLANTIS survey. <i>Arthritis Research and Therapy</i> , 2016, 18, 78.	3.5	52
81	Prognostic Role of Ventricular Ectopic Beats in Systemic Sclerosis: A Prospective Cohort Study Shows ECG Indexes Predicting the Worse Outcome. <i>PLoS ONE</i> , 2016, 11, e0153012.	2.5	48
82	Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 249-252.	0.9	46
83	Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. <i>Arthritis Care and Research</i> , 2011, 63, 711-720.	3.4	46
84	Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung disease. <i>Clinical Respiratory Journal</i> , 2012, 6, 9-17.	1.6	46
85	Characterization of inflammatory cell infiltrate of scleroderma skin: B cells and skin score progression. <i>Arthritis Research and Therapy</i> , 2018, 20, 75.	3.5	45
86	Development of a five-year mortality model in systemic sclerosis patients by different analytical approaches. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, S18-27.	0.8	45
87	Extrasalivary lymphoma development in Sjögren's syndrome: Clonal evolution from parotid gland lymphoproliferation and role of local triggering. <i>Arthritis and Rheumatism</i> , 2003, 48, 3181-3186.	6.7	43
88	PTPN22 1858C>T Polymorphism Distribution in Europe and Association with Rheumatoid Arthritis: Case-Control Study and Meta-Analysis. <i>PLoS ONE</i> , 2011, 6, e24292.	2.5	43
89	Refractory adult-onset Still disease complicated by macrophage activation syndrome and acute myocarditis. <i>Medicine (United States)</i> , 2017, 96, e6656.	1.0	43
90	Cardiac troponin T and NT-proBNP as diagnostic and prognostic biomarkers of primary cardiac involvement and disease severity in systemic sclerosis: A prospective study. <i>European Journal of Internal Medicine</i> , 2019, 60, 46-53.	2.2	43

#	ARTICLE	IF	CITATIONS
91	Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 453-459.	0.9	43
92	Tumor necrosis factor-alpha gene polymorphism in severe and mild-moderate rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2002, 29, 29-33.	2.0	43
93	The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the Quest-RA program. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, 869-77.	0.8	42
94	Widespread clonal B-cell disorder in Sjogren's syndrome predisposing to Helicobacter pylori-related gastric lymphoma. <i>Gastroenterology</i> , 1996, 110, 1969-1974.	1.3	41
95	An autosomal recessive <i>DNASE1L3</i> -related autoimmune disease with unusual clinical presentation mimicking systemic lupus erythematosus. <i>Lupus</i> , 2017, 26, 768-772.	1.6	40
96	When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS). <i>RMD Open</i> , 2016, 2, e000221.	3.8	38
97	JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy. <i>Journal of Leukocyte Biology</i> , 2019, 106, 1063-1068.	3.3	38
98	True primary Sjögren's syndrome in a subset of patients with hepatitis C infection: a model linking chronic infection to chronic sialadenitis. <i>Israel Medical Association Journal</i> , 2002, 4, 1101-5.	0.1	38
99	Computer-Aided Quantification of Interstitial Lung Disease from High Resolution Computed Tomography Images in Systemic Sclerosis: Correlation with Visual Reader-Based Score and Physiologic Tests. <i>BioMed Research International</i> , 2015, 2015, 1-8.	1.9	37
100	Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics register GISEA. <i>Clinical Rheumatology</i> , 2018, 37, 315-321.	2.2	37
101	Collagen Specific T-Cell Repertoire and HLA-DR Alleles: Biomarkers of Active Refractory Rheumatoid Arthritis. <i>EBioMedicine</i> , 2015, 2, 2037-2045.	6.1	36
102	Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 963-969.	0.9	36
103	Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced Osteoporosis Tool (GIOTTO) study. <i>Reumatismo</i> , 2017, 69, 30.	0.9	36
104	Cyclosporine-A plus steroids versus steroids alone in the 12-month treatment of systemic lupus erythematosus. <i>International Journal of Clinical and Laboratory Research</i> , 2000, 30, 67-73.	1.0	35
105	Preliminary Classification of Nonmalignant B Cell Proliferation in Sjögren's Syndrome: Perspectives on Pathobiology and Treatment Based on an Integrated Clinico-Pathologic and Molecular Study Approach. <i>Blood Cells, Molecules, and Diseases</i> , 2001, 27, 757-766.	1.4	35
106	Colour Doppler ultrasonography evaluation of vascularization in the wrist and finger joints in rheumatoid arthritis patients and healthy subjects. <i>European Journal of Radiology</i> , 2012, 81, 1834-1838.	2.6	35
107	Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. <i>Frontiers in Pharmacology</i> , 2019, 10, 296.	3.5	35
108	Toll-Like Receptor 4 Mediates Endothelial Cell Activation Through NF- κ B but Is Not Associated with Endothelial Dysfunction in Patients with Rheumatoid Arthritis. <i>PLoS ONE</i> , 2014, 9, e99053.	2.5	35

#	ARTICLE	IF	CITATIONS
109	The γ 670G>A polymorphism in the <i>FAS</i> gene promoter region influences the susceptibility to systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 584-590.	0.9	34
110	Biomarkers of Good EULAR Response to the B Cell Depletion Therapy in All Seropositive Rheumatoid Arthritis Patients: Clues for the Pathogenesis. <i>PLoS ONE</i> , 2012, 7, e40362.	2.5	34
111	γ 238 and +489 TNF- α along with TNF-RII gene polymorphisms associate with the diffuse phenotype in patients with Systemic Sclerosis. <i>Immunology Letters</i> , 2005, 96, 103-108.	2.5	33
112	Osteoporosis and bone metabolism in postmenopausal women with osteoarthritis of the hand. <i>Menopause</i> , 2006, 13, 462-466.	2.0	33
113	Modeling the Ternary Complex TCR-V β 2/CollagenII(261-273)/HLA-DR4 Associated with Rheumatoid Arthritis. <i>PLoS ONE</i> , 2010, 5, e11550.	2.5	32
114	The potential role of Th17 in mediating the transition from acute to chronic autoimmune inflammation: rheumatoid arthritis as a model. <i>Discovery Medicine</i> , 2011, 11, 413-24.	0.5	32
115	Thrombogenicity of TNF- α in rheumatoid arthritis defined through biological probes: TNF- α blockers. <i>Autoimmunity Reviews</i> , 2004, 3, 261-266.	5.8	30
116	<i>Helicobacter pylori</i> Associated Antigastric Autoantibodies: Role in Sjogren's Syndrome Gastritis. <i>Helicobacter</i> , 2004, 9, 46-53.	3.5	30
117	Prevalence and Determinants of Peripheral Microvascular Endothelial Dysfunction in Rheumatoid Arthritis Patients: A Multicenter Cross-Sectional Study. <i>Mediators of Inflammation</i> , 2018, 2018, 1-8.	3.0	30
118	ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature. <i>Arthritis Research and Therapy</i> , 2009, 11, R163.	3.5	29
119	Leflunomide Treatment in Elderly Patients with Rheumatoid or Psoriatic Arthritis. <i>Drugs and Aging</i> , 2009, 26, 395-402.	2.7	29
120	Driving chronicity in rheumatoid arthritis: perpetuating role of myeloid cells. <i>Clinical and Experimental Immunology</i> , 2018, 193, 13-23.	2.6	29
121	The polymerase chain reaction detects B cell clonalities in patients with Sjögren's syndrome and suspected malignant lymphoma. <i>Journal of Rheumatology</i> , 1994, 21, 1497-501.	2.0	29
122	Efficacy of cyclosporin-A in the long-term management of thrombocytopenia associated with systemic lupus erythematosus. <i>Lupus</i> , 2006, 15, 76-79.	1.6	28
123	Interstitial granulomatous dermatitis in rheumatoid arthritis responsive to etanercept. <i>Clinical Rheumatology</i> , 2010, 29, 99-101.	2.2	28
124	Infections, B cell receptor activation and autoimmunity: Different check-point impairments lead to autoimmunity, clonal B cell expansion and fibrosis in different immunological settings. <i>Autoimmunity Reviews</i> , 2007, 7, 109-113.	5.8	27
125	Renal interstitial cells, proteinuria and progression of lupus nephritis: new frontiers for old factors. <i>Lupus</i> , 2008, 17, 533-540.	1.6	27
126	B-Cell Subsets in the Joint Compartments of Seropositive and Seronegative Rheumatoid Arthritis (RA) and No-RA Arthritides Express Memory Markers and ZAP70 and Characterize the Aggregate Pattern Irrespectively of the Autoantibody Status. <i>Molecular Medicine</i> , 2011, 17, 901-909.	4.4	27

#	ARTICLE	IF	CITATIONS
127	Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 294.	3.5	27
128	Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2017, 36, 2655-2665.	2.2	27
129	CISEA: an Italian biological agents registry in rheumatology. <i>Reumatismo</i> , 2011, 63, 155-64.	0.9	26
130	Temporal ultrasonography findings in temporal arteritis: early disappearance of halo sign after only 2 days of steroid treatment. <i>Rheumatology</i> , 2013, 52, 622-622.	1.9	26
131	Local cytokine expression in the progression toward B cell malignancy in Sjögren's syndrome. <i>Journal of Rheumatology</i> , 1995, 22, 1674-80.	2.0	26
132	Polymorphism of immunoglobulin enhancer element HS1,2A: allele *2 associates with systemic sclerosis. Comparison with HLA-DR and DQ allele frequency. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1210-1215.	0.9	25
133	Î2-thymosins and interstitial lung disease: study of a scleroderma cohort with a one-year follow-up. <i>Respiratory Research</i> , 2011, 12, 22.	3.6	25
134	Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinaemic vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S48-52.	0.8	25
135	Controlled multicenter trial of tiopronin and D-penicillamine for rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1982, 25, 923-929.	6.7	24
136	Synovial Predictors of Differentiation to Definite Arthritis in Patients With Seronegative Undifferentiated Peripheral Inflammatory Arthritis: microRNA Signature, Histological, and Ultrasound Features. <i>Frontiers in Medicine</i> , 2018, 5, 186.	2.6	24
137	Proteomic approaches to Sjögren's syndrome: A clue to interpret the pathophysiology and organ involvement of the disease. <i>Autoimmunity Reviews</i> , 2010, 9, 622-626.	5.8	23
138	Polymorphisms of the IgH enhancer HS1.2 and risk of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1309-1315.	0.9	23
139	Cilostazol improves the response to ischemia in diabetic mice by a mechanism dependent on PPARÎ³. <i>Molecular and Cellular Endocrinology</i> , 2013, 381, 80-87.	3.2	23
140	Quality indicators in rheumatoid arthritis: results from the METEOR database. <i>Rheumatology</i> , 2015, 54, 1630-1639.	1.9	23
141	Chemerin and PEDF Are Metaflammation-Related Biomarkers of Disease Activity and Obesity in Rheumatoid Arthritis. <i>Frontiers in Medicine</i> , 2018, 5, 207.	2.6	23
142	Differential synovial tissue biomarkers among psoriatic arthritis and rheumatoid factor/anti-citrulline antibody-negative rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 116.	3.5	23
143	Anti-Müllerian hormone serum levels in systemic lupus erythematosus patients: Influence of the disease severity and therapy on the ovarian reserve. <i>Endocrine</i> , 2019, 63, 369-375.	2.3	23
144	Haematopoietic stem cell transplantation (HSCT) in a patient with Sjögren's syndrome and lung malt lymphoma cured lymphoma not the autoimmune disease. <i>Annals of the Rheumatic Diseases</i> , 2001, 60, 173b-173.	0.9	22

#	ARTICLE	IF	CITATIONS
145	MR imaging of atlantoaxial joint in early rheumatoid arthritis. <i>Radiologia Medica</i> , 2010, 115, 1111-1120.	7.7	22
146	Inclusion of Synovial Tissueâ€Derived Characteristics in a Nomogram for the Prediction of Treatment Response in Treatmentâ€Naive Rheumatoid Arthritis Patients. <i>Arthritis and Rheumatology</i> , 2021, 73, 1601-1613.	5.6	22
147	Position paper of Italian rheumatologists on the use of biosimilar drugs. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 1-4.	0.8	22
148	Lack of Hcv Infection in Malignant, Cells Refutes the Hypothesis of a Direct Transforming Action of the Virus in the Pathogenesis of Hcv-Associated B-Cell Nhl's. <i>Tumori</i> , 2002, 88, 400-406.	1.1	21
149	Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register. <i>Joint Bone Spine</i> , 2014, 81, 508-512.	1.6	21
150	Life-threatening arrhythmias in a scleroderma patient: the role of myocardial inflammation in arrhythmic outburst. <i>Scandinavian Journal of Rheumatology</i> , 2017, 46, 78-80.	1.1	21
151	Somatomedin C (insulin-like growth factor 1) levels decrease during acute changes of stress related hormones. Relevance for fibromyalgia. <i>Journal of Rheumatology</i> , 1994, 21, 1332-4.	2.0	21
152	Hepatocyte growth factor and transforming growth factor β 1 ratio at baseline can predict early response to cyclophosphamide in systemic lupus erythematosus nephritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 3633-3639.	6.7	20
153	Memory B cell subsets and plasmablasts are lower in early than in long-standing Rheumatoid Arthritis. <i>BMC Immunology</i> , 2014, 15, 28.	2.2	20
154	Is ACPA positivity the main driver for rheumatoid arthritis treatment? Pros and cons. <i>Autoimmunity Reviews</i> , 2017, 16, 1096-1102.	5.8	20
155	Immune-Guided Therapy of COVID-19. <i>Cancer Immunology Research</i> , 2022, 10, 384-402.	3.4	20
156	Rheumatoid arthritis and Alzheimer's disease: genetic and epigenetic links in inflammatory regulation. <i>Discovery Medicine</i> , 2012, 14, 379-88.	0.5	20
157	Citrullination: the loss of tolerance and development of autoimmunity in rheumatoid arthritis. <i>Reumatismo</i> , 2011, 60, 85-94.	0.9	19
158	Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability. <i>Clinical Rheumatology</i> , 2016, 35, 2649-2656.	2.2	19
159	B cell activating factor (BAFF) and BAFF receptors: fakes and facts. <i>Clinical and Experimental Immunology</i> , 2017, 190, 291-292.	2.6	19
160	Tumour-associated antigens in systemic sclerosis patients with interstitial lung disease: association with lung involvement and cancer risk. <i>Rheumatology</i> , 2015, 54, 1991-1999.	1.9	18
161	Biomolecular features of inflammation in obese rheumatoid arthritis patients: management considerations. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 751-762.	3.0	18
162	QTc interval prolongation in Systemic Sclerosis: Correlations with clinical variables and arrhythmic risk. <i>International Journal of Cardiology</i> , 2017, 239, 33.	1.7	18

#	ARTICLE	IF	CITATIONS
163	Free light chains of immunoglobulins in patients with systemic sclerosis: correlations with lung involvement and inflammatory milieu. <i>Journal of Clinical Pathology</i> , 2018, 71, 620-625.	2.0	18
164	Adiposity, joint and systemic inflammation: the additional risk of having a metabolic syndrome in rheumatoid arthritis. <i>Swiss Medical Weekly</i> , 2011, 141, w13211.	1.6	18
165	The Relevance of VDJ PCR Protocols in Detecting B-Cell Clonal Expansion in Lymphomas and Other Lymphoproliferative Disorders. <i>Tumori</i> , 1995, 81, 405-409.	1.1	17
166	The role of high-mobility group box protein 1 in collagen antibody-induced arthritis is dependent on vascular endothelial growth factor. <i>Clinical and Experimental Immunology</i> , 2016, 184, 62-72.	2.6	17
167	The Role of High-Mobility Group Box-1 and Its Crosstalk with Microbiome in Rheumatoid Arthritis. <i>Mediators of Inflammation</i> , 2017, 2017, 1-11.	3.0	17
168	Overweight/obesity affects histological features and inflammatory gene signature of synovial membrane of Rheumatoid Arthritis. <i>Scientific Reports</i> , 2019, 9, 10420.	3.3	17
169	The pathogenesis of microthrombi in COVID-19 cannot be controlled by DOAC: NETosis should be the target. <i>Journal of Internal Medicine</i> , 2021, 289, 420-421.	6.0	17
170	Increase of bone mineral density and anabolic variables in patients with rheumatoid arthritis resistant to methotrexate after cyclosporin A therapy. <i>Journal of Rheumatology</i> , 1996, 23, 1539-42.	2.0	17
171	Improved endothelial function after endothelin receptor blockade in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2009, 60, 1840-1844.	6.7	16
172	Function and dysfunction of dendritic cells in autoimmune rheumatic diseases. <i>Human Immunology</i> , 2009, 70, 360-373.	2.4	16
173	Diagnostic performance of anti-citrullinated peptide antibodies for the diagnosis of rheumatoid arthritis: the relevance of likelihood ratios. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 829-34.	2.3	16
174	Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs. <i>Rheumatology</i> , 2012, 51, v12-v21.	1.9	16
175	To switch or not to switch after a poor response to a TNF α blocker? It is not only a matter of ACR20 OR ACR50. <i>Autoimmunity Reviews</i> , 2012, 11, 558-562.	5.8	16
176	Environmental Pollution by Benzene and PM10 and Clinical Manifestations of Systemic Sclerosis: A Correlation Study. <i>International Journal of Environmental Research and Public Health</i> , 2017, 14, 1297.	2.6	16
177	Adherence to Treat-to-target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort. <i>Journal of Rheumatology</i> , 2020, 47, 809-819.	2.0	16
178	Checkpoint inhibitors (CPI) and autoimmune chronic inflammatory diseases (ACIDs): tolerance and loss of tolerance in the occurrence of immuno-rheumatologic manifestations. <i>Clinical Immunology</i> , 2020, 214, 108395.	3.2	16
179	Pathogenetic, clinical and pharmaco-economic assessment in rheumatoid arthritis (RA). <i>Internal and Emergency Medicine</i> , 2011, 6, 11-15.	2.0	15
180	Proteome analysis of biological fluids from autoimmune-rheumatological disorders. <i>Proteomics - Clinical Applications</i> , 2011, 5, 78-89.	1.6	15

#	ARTICLE	IF	CITATIONS
181	Detection of bone erosions in early rheumatoid arthritis: 3D ultrasonography versus computed tomography. <i>Clinical Rheumatology</i> , 2015, 34, 1181-1186.	2.2	15
182	Evidence-based algorithm for diagnosis and assessment in psoriatic arthritis: results by Italian DELphi in psoriatic Arthritis (IDEA). <i>Reumatismo</i> , 2016, 68, 126-136.	0.9	15
183	Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis. <i>RMD Open</i> , 2018, 4, e000667.	3.8	15
184	Haemophilus parasuis (Glaesserella parasuis) as a Potential Driver of Molecular Mimicry and Inflammation in Rheumatoid Arthritis. <i>Frontiers in Medicine</i> , 2021, 8, 671018.	2.6	15
185	Mycophenolate mofetil and intravenous dexamethasone in the treatment of persistent lupus myelitis. <i>Journal of Rheumatology</i> , 2007, 34, 588-91.	2.0	15
186	Synovial B cells of rheumatoid arthritis express ZAP-70 which increases the survival and correlates with the inflammatory and autoimmune phenotype. <i>Clinical Immunology</i> , 2009, 131, 98-108.	3.2	14
187	Baseline Shoulder Ultrasonography Is Not a Predictive Marker of Response to Glucocorticoids in Patients with Polymyalgia Rheumatica: A 12-month Followup Study. <i>Journal of Rheumatology</i> , 2017, 44, 241-247.	2.0	14
188	Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs. <i>Joint Bone Spine</i> , 2018, 85, 455-459.	1.6	14
189	Colimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA. <i>Joint Bone Spine</i> , 2021, 88, 105062.	1.6	14
190	The B side of rheumatoid arthritis pathogenesis. <i>Pharmacological Research</i> , 2019, 149, 104465.	7.1	13
191	A vascular endothelial growth factor deficiency characterises scleroderma lung disease. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1461-1465.	0.9	12
192	The prognostic significance of the Birmingham Vasculitis Activity Score (BVAS) with systemic vasculitis patients transferred to the intensive care unit (ICU). <i>Medicine (United States)</i> , 2016, 95, e5506.	1.0	12
193	Interleukin-6 and IgA-rheumatoid factor are crucial for baseline erosiveness, and anti-citrullinated peptide antibodies for radiographic progression in early rheumatoid arthritis treated according to a treat-to-target strategy. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 351-359.	1.1	11
194	Basic immunology may lead to translational therapeutic rationale: SARS-CoV-2 and rheumatic diseases. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13342.	3.4	11
195	Comprehensive review on intravertebral intraspinal, intrajoint, and intradiscal vacuum phenomenon: From anatomy and physiology to pathology. <i>Modern Rheumatology</i> , 2021, 31, 303-311.	1.8	11
196	Absence of human parvovirus B19 DNA in myoepithelial sialadenitis of primary Sjogren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 855-856.	0.9	10
197	Abatacept in the treatment of psoriatic arthritis: biological and clinical profiles of the responders. <i>Immunotherapy</i> , 2018, 10, 807-821.	2.0	10
198	Selective Inhibitors of T Cell Receptor Recognition of Antigen-MHC Complexes for Rheumatoid Arthritis. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 644-649.	2.8	10

#	ARTICLE	IF	CITATIONS
199	Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA. Clinical and Experimental Rheumatology, 2019, 37, 649-655.	0.8	10
200	The UltraSound-Clinical ARthritis Activity (US-CLARA) index: Properties of a new composite disease activity index for rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 2018, 47, 619-629.	3.4	9
201	Body mass index as a driver of selection of biologic therapy in rheumatoid arthritis. Results from the US-CLARA study. European Journal of Internal Medicine, 2019, 66, 57-61.	2.2	9
202	Which B-cell subset should we target in lupus?. Annals of the Rheumatic Diseases, 2013, 72, 1891-1892.	0.9	8
203	Biomarkers of Joint Damage in Rheumatoid Arthritis: Where Are We in 2013?. Journal of Rheumatology, 2013, 40, 1244-1246.	2.0	8
204	Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register). Annals of the Rheumatic Diseases, 2014, 73, e31-e31.	0.9	8
205	Immunosuppressive Therapy (Methotrexate or Cyclophosphamide) in Combination with Corticosteroids in the Treatment of Giant Cell Arteritis: Comparison with Corticosteroids Alone. Journal of the American Geriatrics Society, 2016, 64, 672-374.	2.6	8
206	Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial. RMD Open, 2019, 5, e000934.	3.8	8
207	Systemic Bone Density at Disease Onset Is Associated With Joint Erosion Progression in Early Naive to Treatment Rheumatoid Arthritis: A Prospective 12-Month Follow-Up Open-Label Study. Frontiers in Medicine, 2021, 8, 613889.	2.6	8
208	Cyclosporin A increases somatomedin C insulin-like growth factor I levels in chronic rheumatic diseases. Journal of Rheumatology, 1995, 22, 1060-4.	2.0	8
209	Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2017, 35, 1018-1028.	0.8	8
210	Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians. Journal of Clinical Rheumatology, 2015, 21, 349-354.	0.9	7
211	Microvascular heart involvement in systemic autoimmune diseases: The purinergic pathway and therapeutic insights from the biology of the diseases. Autoimmunity Reviews, 2019, 18, 317-324.	5.8	7
212	Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies. Frontiers in Medicine, 2020, 7, 553075.	2.6	7
213	Pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatology, The, 2020, 2, e458.	3.9	7
214	Pharmacogenetics/pharmacogenomics and antirheumatic drugs in rheumatology. Pharmacogenomics, 2004, 5, 1107-1116.	1.3	6
215	Pharmacogenetic of antirheumatic treatments: clinical implications. Pharmacogenomics Journal, 2007, 7, 2-9.	2.0	6
216	Do we need to apply a T2T strategy even in ACPA-negative early rheumatoid arthritis? YES. RMD Open, 2016, 2, e000263.	3.8	6

#	ARTICLE	IF	CITATIONS
217	Correspondence on "Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis". Annals of the Rheumatic Diseases, 2023, 82, e5-e5.	0.9	6
218	Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?. Annals of the Rheumatic Diseases, 2021, 80, e29-e29.	0.9	6
219	The chronic arthritis systemic index: a nomogram to assess the activity and severity of chronic arthritis. Arthritis and Rheumatism, 1993, 36, 1180-1181.	6.7	5
220	CYCLOSPORINE A PHARMACOKINETICS IN RHEUMATOID ARTHRITIS PATIENTS AFTER 6 MONTHS OF METHOTREXATE THERAPY. Pharmacological Research, 1999, 40, 483-486.	7.1	5
221	Atlantoepistrophic magnetic resonance imaging involvement in early rheumatoid arthritis: An aggressive tight control therapy not fully arresting the disease. Arthritis Care and Research, 2011, 63, 1629-1633.	3.4	5
222	ZAP-70+ B Cell Subset Influences Response to B Cell Depletion Therapy and Early Repopulation in Rheumatoid Arthritis. Journal of Rheumatology, 2012, 39, 2276-2285.	2.0	5
223	Association between the response to B cell depletion therapy and the allele*2 of the HS1,2A enhancer in seropositive rheumatoid arthritis patients. Reumatismo, 2012, 64, 368-73.	0.9	5
224	Thymosin α 1 and α 2 in Sjögren's syndrome: saliva proteomics and minor salivary glands expression. Arthritis Research and Therapy, 2016, 18, 229.	3.5	5
225	Should rheumatoid factor (RF) (and antinuclear antibodies (ANA)) become routinary screening test for morbidities in the general population?. Autoimmunity Reviews, 2018, 17, 636-638.	5.8	5
226	Ultrasound assessment as predictor of disease relapse in children and adults with arthritis in clinical stable remission: new findings but still unmet needs. Annals of the Rheumatic Diseases, 2018, 77, 1391-1393.	0.9	5
227	Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries. Clinical and Experimental Rheumatology, 2017, 35, 660-665.	0.8	5
228	Peripheral blood CD4posCD25posFoxP3pos cells and inflammatory cytokines as biomarkers of response in rheumatoid arthritis patients treated with CTLA4-Ig. Arthritis Research and Therapy, 2022, 24, .	3.5	5
229	Tofacitinib for rheumatoid arthritis. Lancet, The, 2013, 381, 1812.	13.7	4
230	Could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: pros and cons?. Arthritis Research and Therapy, 2016, 18, 126.	3.5	4
231	CTLA-4 Ig as an effective treatment in a patient with type I diabetes mellitus and seropositive rheumatoid arthritis. Clinical and Experimental Rheumatology, 2016, 34, 315-7.	0.8	4
232	OP0178...The Body Mass Index: A Determinant of Remission in Early Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2013, 72, A113.2-A113.	0.9	3
233	Is Citrullination Required for the Presence of Restricted Clonotypes Reacting With Type II Collagen? Comment on the Article by Chemin et al. Arthritis and Rheumatology, 2016, 68, 2052-2053.	5.6	3
234	Unmet Needs in the Treatment of RA in the Era of Jak-i: IDRA (Italian Delphi Rheumatoid Arthritis) Consensus. BioMed Research International, 2018, 2018, 1-10.	1.9	3

#	ARTICLE	IF	CITATIONS
235	Measuring the Tâ€cell downâ€regulation of TCRâ€zeta, ZAPâ€70 and CD28 in arthritis patients: An old tool for new biomarkers. European Journal of Immunology, 2019, 49, 2195-2203.	2.9	3
236	More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia. Annals of the Rheumatic Diseases, 2022, 81, e157-e157.	0.9	3
237	Factors Predicting Early Failure of Etanercept in Rheumatoid Arthritis: An Analysis From the Gruppo Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis) Registry. Archives of Rheumatology, 2020, 35, 163-169.	0.9	3
238	Outcomes and Findings of the International Rheumatoid Arthritis (RA) BIODAM Cohort for Validation of Soluble Biomarkers in RA. Journal of Rheumatology, 2020, 47, 796-808.	2.0	3
239	Morbidity and Mortality From COVIDâ€19 Are Not Increased Among Children or Patients With Autoimmune Rheumatic Diseaseâ€Possible Immunologic Rationale: Comment on the Article by Henderson et al. Arthritis and Rheumatology, 2020, 72, 1772-1774.	5.6	3
240	Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry. Clinical Rheumatology, 2021, 40, 4039-4047.	2.2	3
241	Gut microbiota analysis in systemic sclerosis according to disease characteristics and nutritional status. Clinical and Experimental Rheumatology, 2020, 38 Suppl 125, 73-84.	0.8	3
242	Infectious agents breaking the immunological tolerance: The holy grail in rheumatoid arthritis reconsidered. Autoimmunity Reviews, 2022, 21, 103102.	5.8	3
243	Analysis of response to infliximab in ankylosing spondylitis according to the axial and/or peripheral involvement: autoantibodies and drop outs are more frequent in the peripheral subset. Annals of the Rheumatic Diseases, 2007, 66, 427-428.	0.9	2
244	Should We Consider Tumor Necrosis Factor as the Only Target in Spondyloarthritis?. Journal of rheumatology Supplement, The, 2012, 89, 94-96.	2.2	2
245	The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts. Autoimmunity Reviews, 2018, 17, 1251-1258.	5.8	2
246	HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?. RMD Open, 2020, 6, e001171.	3.8	2
247	Correspondence on â€Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registryâ€by Sparks<i>et al</i>. Annals of the Rheumatic Diseases, 2023, 82, e157-e157.	0.9	2
248	Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: results of an Italian observational study. Clinical and Experimental Rheumatology, 2017, 35, 919-928.	0.8	2
249	Lupus anticoagulant and ischemic myocardial microangiopathy in rheumatoid arthritis. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 339-343.	3.3	1
250	B cell depletion and a T cell-targeted therapy allows to control the sudden onset of diabetes and lupus, without steroids. Acta Diabetologica, 2008, 45, 195-196.	2.5	1
251	Infections, rheumatisms and autoimmunity. Future Rheumatology, 2008, 3, 223-225.	0.2	1
252	Biologics use in sle in 23 centers â€ data from the international registry for biologics in SLE. Annals of the Rheumatic Diseases, 2012, 71, A9.1-A9.	0.9	1

#	ARTICLE	IF	CITATIONS
253	THU0532â€¦Distribution of Body Mass Index and Metabolic Syndrome in Patients with Inflammatory Autoimmune Diseases from a Single Italian Centre. Annals of the Rheumatic Diseases, 2013, 72, A344.1-A344.	0.9	1
254	AB0465â€¦Etanercept therapy in rheumatoid arthritis patients with moderate or severe disease activity. Annals of the Rheumatic Diseases, 2013, 71, 664.5-664.	0.9	1
255	Response to letter by Aramugakaniet al. Annals of the Rheumatic Diseases, 2014, 73, e21-e21.	0.9	1
256	THU0525â€¦Metaflammation, PEDF and Chemerin: Potential Systemic Factors Which Link Obesity to Response to Therapy in Early Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2014, 73, 364.3-365.	0.9	1
257	Weight Loss, The Obesity Paradox in Rheumatoid Arthritis: Is It a Paradox? Comment on the Article by Baker et al. Arthritis and Rheumatology, 2016, 68, 553-553.	5.6	1
258	Comment on â€œTumor necrosis factor-Î± antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series studyâ€. Clinical Rheumatology, 2016, 35, 839-840.	2.2	1
259	FRI0388â€¦SECUKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ANKYLOSING SPONDYLITIS, IRRESPECTIVE OF TIME SINCE FIRST DIAGNOSIS: POOLED RESULTS FROM THE SECUKINUMAB PHASE 3 TRIAL PROGRAM. , 2019, , .		1
260	Comment on: Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis. Rheumatology, 2020, 59, 1782-1783.	1.9	1
261	RAASI, NSAIDs, antidiabetics, and anticoagulants: More data needed to be labeled as harmful or neutral in SARS-CoV-2 infection. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, e2025609118.	7.1	1
262	Cryoprecipitation.in vitro studies on fibronectin as an independent cryoprecipitagogue. Research in Clinic and Laboratory, 1986, 16, 315-20.	0.3	1
263	Indomethacin-Related Serum Sickness-Like Illness with IgM Lambda Cryoparaprotein?. Acta Haematologica, 1985, 73, 45-46.	1.4	0
264	Pharmacogenetics, Target Molecules, and Biological Anti-Rheumatic Drugs in Autoimmune/Chronic Inflammatory Rheumatic Diseases. Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics, 2006, 4, 105-111.	0.3	0
265	Introduction. Autoimmunity Reviews, 2007, 7, 95.	5.8	0
266	Chapter 8 Gastrointestinal Involvement in Systemic Vasculitis. Handbook of Systemic Autoimmune Diseases, 2008, 8, 83-298.	0.1	0
267	Association of autoimmune diseases to allele 2 of the 3' immunoglobulin HS1.2 enhancer bearing an NF-ÎB binding site.. Nature Precedings, 2009, , .	0.1	0
268	B cell receptor repertoire analysis in clinically involved and uninvolved skin of systemic sclerosis patients treated with CD20 depletion therapy: baseline and follow-up. Annals of the Rheumatic Diseases, 2011, 70, A62-A63.	0.9	0
269	FRI0096â€¦Haq baseline values in an international registry of ra patients during the era of biologic therapies: the 2013 meteor database.. Annals of the Rheumatic Diseases, 2013, 72, A402.1-A402.	0.9	0
270	AB0770â€¦Rheuma-card: involvement of the patient through a secure systems access into the treat to target strategy in rheumatology.. Annals of the Rheumatic Diseases, 2013, 72, A1025.1-A1025.	0.9	0

#	ARTICLE	IF	CITATIONS
271	SAT0199â€¦An estimate of the proportion of patients with sle receiving off-label treatment with rituximab in european countries. Annals of the Rheumatic Diseases, 2013, 71, 539.1-539.	0.9	0
272	SAT0175â€¦Results of the Classification Criteria for Cryoglobulinemic Vasculitis Validation Study. Annals of the Rheumatic Diseases, 2013, 72, A640.2-A641.	0.9	0
273	OP0274â€¦Cryoglobulinemic Vasculitis and Primary sjögren's Syndrome are Independent Risk Factors for Lymphoma in a Large Worldwide Population of Patients with Positive Serum Cryoglobulins. Annals of the Rheumatic Diseases, 2015, 74, 175.3-176.	0.9	0
274	RHEUMATOID ARTHRITIS: PATHOGENESIS204.â€¦CHARACTERIZATION OF SYNOVIUM TISSUES MACROPHAGE OF RHEUMATOID ARTHRITIS PATIENTS. Rheumatology, 2017, 56, .	1.9	0
275	O3.13â€¦Synovial tissue of ra patients in remission contains a unique population of regulatory macrophages. , 2017, , .		0
276	OP0208â€¦Synovial tissue of ra patients in remission contains a unique population of regulatory macrophages. , 2017, , .		0
277	THU0366â€¦Gastrointestinal infections in patients with spondyloarthritis treated with anti-tnf drugs: results of gisea register. , 2017, , .		0
278	168â€¦Body mass index does not influence the efficacy of abatacept in patients with psoriatic arthritis: results from the ASTRAEA trial. Rheumatology, 2018, 57, .	1.9	0
279	SAT0003â€¦Synovial tissue cd1c+ dendritic cells in rheumatoid arthritis express high levels of the epigenetic regulator of inflammation, microrna-155 and inflammatory cytokines. , 2018, , .		0
280	PS1:9â€¦B cell subpopulations in lupus nephritis patients: correlations with disease onset and outcomes. , 2018, , .		0
281	AB0253â€¦BIOMARKERS OF CLINICAL RESPONSE TO IL6-R BLOCKADE IN DMARDS INCOMPLETE RESPONDERS (AR-BIOM TRIAL): IL23 AND BAFF AS BIOLOGICAL TARGETS, AND ALBUMIN AS BIOLOGICAL PREDICTOR. , 2019, , .		0
282	SAT0073â€¦STAT3/STAT5 BALANCE AS A BIOMARKER IN RA: CTLA4-IG AND T CELL DIFFERENTIATION THROUGH STAT SIGNALING. , 2019, , .		0
283	AB0515â€¦OBESITY AND WEIGHT LOSS IMPACT IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS. , 2019, , .		0
284	AB0460â€¦USE OF PLATELET RICH PLASMA (PRP) IN TREATMENT OF DRY EYE SYNDROME IN THE PATIENTS WITH SJÖGREN SYNDROME: PRELIMINARY RESULTS. , 2019, , .		0
285	SAT0201â€¦CARDIOVASCULAR EVENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): THE ROLE OF TRADITIONAL CARDIOVASCULAR RISK AND SLE-RELATED FACTORS. , 2019, , .		0
286	O14â€¦Semi-quantitative assessment of synovial inflammation on US guided synovial membrane biopsy is contingent to disease phase, autoimmune profile and treatment response in RA: a large single center experience. Rheumatology, 2020, 59, .	1.9	0
287	P234â€¦Characterisation of human synovial tissue dendritic cells in rheumatoid arthritis patients. Rheumatology, 2020, 59, .	1.9	0
288	P189â€¦Antiphospholipid antibodies and vascular renal lesions as prognostic factors in lupus nephritis. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
289	Rheumatologic Symptoms in Patients with Mixed Cryoglobulinemia. , 2012, , 185-190.		0
290	THU0028â€¦Interleukin-6 receptor inhibition, as first-line b-dmard, affects b cell subpopulations distribution through epigenetic modifications in rheumatoid arthritispatients. , 2018, , .		0
291	THU0441â€¦Endothelial dysfunction in polymyalgia rheumatica. , 2018, , .		0
292	AB0202â€¦Glucocorticoids in the initial treat-to-target strategy of early rheumatoid arthritis. , 2018, , .		0
293	SAT0223â€¦Predictive factors of early failure to first line treatment with methotrexate in patients with rheumatoid arthritis. results from the gisea registry.. , 2018, , .		0
294	SAT0193â€¦Early discontinuation of first line biological treatment with etanercept in patients with rheumatoid arthritis: results from the italian gisea registry. , 2018, , .		0
295	THU0234â€¦Bmi does not affect clinical outcome in psoriatic arthritis patients treated with tight control strategy. , 2018, , .		0
296	FRI0002â€¦Analysis of b cells and t cells subpopulations and collagen specific t cell repertoire in juvenile idiopathic arthritis patients. , 2018, , .		0
297	AB0759â€¦The assessment of gastrointestinal tract involvement through ucla sctc git 2.0 questionnaire identifies scleroderma patients with reduced bone mineral density. , 2018, , .		0
298	FRI0574â€¦RENAL TISSUE EPIGENETIC BIOMARKERSâ€™ CHARACTERIZATION IN PATIENTS WITH LUPUS NEPHRITIS AS PARAMETERS OF DISEASE ACTIVITY, REMISSION AND FLARE. Annals of the Rheumatic Diseases, 2020, 79, 889.2-890.	0.9	0
299	SAT0224â€¦ANTIPHOSPHOLIPID ANTIBODIES AND VASCULAR RENAL LESIONS AS PROGNOSTIC FACTORS IN LUPUS NEPHRITIS. Annals of the Rheumatic Diseases, 2020, 79, 1055.3-1055.	0.9	0
300	THU0287â€¦EVALUATION OF PREDICTIVE FACTORS OF WORSE PROGNOSIS IN LUPUS NEPHRITIS: FOCUS ON NEW PATHOGENETIC PATHWAYS. Annals of the Rheumatic Diseases, 2020, 79, 370.3-370.	0.9	0
301	AB0102â€¦SPECIALIZED PRO-RESOLVING MEDIATOR RECEPTORS AS INFLAMMATORY RESOLUTION BIOMARKERS IN RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases, 2020, 79, 1350.3-1350.	0.9	0